Search hospitals
>
Pennsylvania
>
Pittsburgh
University of Pittsburgh Cancer Institute (UPCI)
Claim this profile
Pittsburgh, Pennsylvania 15232
Global Leader in Lung Cancer
Global Leader in Cancer
Conducts research for Pancreatic Cancer
Conducts research for Melanoma
Conducts research for Breast Cancer
1081 reported clinical trials
86 medical researchers
Summary
University of Pittsburgh Cancer Institute (UPCI) is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Lung Cancer, Cancer, Pancreatic Cancer, Melanoma, Breast Cancer and other specialties. University of Pittsburgh Cancer Institute (UPCI) is involved with conducting 1,081 clinical trials across 802 conditions. There are 86 research doctors associated with this hospital, such as Liza C. Villaruz, Jason Luke, MD, Diwakar Davar, MD, and Adam Brufsky, MD.
Area of expertise
Lung Cancer
University of Pittsburgh Cancer Institute (UPCI) has run 201 trials for Lung Cancer. Some of their research focus areas include:
Cancer
University of Pittsburgh Cancer Institute (UPCI) has run 176 trials for Cancer. Some of their research focus areas include:
Top PIs
Liza C. Villaruz
University of Pittsburgh Cancer Institute (UPCI)
7 years of reported clinical research
Jason Luke, MD
University of Pittsburgh Medical Center
1 year of reported clinical research
Diwakar Davar, MD
UPMC Hillman Cancer Center
7 years of reported clinical research
Adam Brufsky, MD
University of Pittsburgh Cancer Institute (UPCI)
2 years of reported clinical research
Clinical Trials running at University of Pittsburgh Cancer Institute (UPCI)
Lung Cancer
Skin Cancer
Cancer
Prostate Cancer
Colorectal Cancer
Kidney Cancer
Breast Cancer
Breast cancer
Testicular cancer
Myelofibrosis
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Durvalumab
for Lung Cancer
This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.
Recruiting
2 awards
Phase 3
8 criteria
Ceralasertib + Durvalumab
for Non-Small Cell Lung Cancer
This phase III trial compares the effect of adding AZD6738 to durvalumab versus durvalumab alone to increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery. AZD6738 may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell growth. Durvalumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Adding AZD6738 to durvalumab may increase time without cancer in patients with non-small cell lung cancer, following treatment with chemotherapy and surgery.
Recruiting
2 awards
Phase 3
10 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at University of Pittsburgh Cancer Institute (UPCI)?
University of Pittsburgh Cancer Institute (UPCI) is a medical facility located in Pittsburgh, Pennsylvania. This center is recognized for care of Lung Cancer, Cancer, Pancreatic Cancer, Melanoma, Breast Cancer and other specialties. University of Pittsburgh Cancer Institute (UPCI) is involved with conducting 1,081 clinical trials across 802 conditions. There are 86 research doctors associated with this hospital, such as Liza C. Villaruz, Jason Luke, MD, Diwakar Davar, MD, and Adam Brufsky, MD.
Where is University of Pittsburgh Cancer Institute (UPCI) located?
The University of Pittsburgh Cancer Institute (UPCI) is situated at 5150 Centre Ave, Pittsburgh, PA 15232. Access is convenient via I-376 W, exiting at Bates St, then turning left onto S Bates St which continues onto Centre Ave, where the hospital is located on the right.
Who should I call to ask about financial aid or insurance network?
The University of Pittsburgh Cancer Institute (UPCI) offers financial assistance through UPMC's Financial Assistance Program. To apply, obtain the UPMC Financial Assistance Application form by calling 1-800-371-8359 (option 2), downloading it from the UPMC website, or requesting it at the hospital or physician's office. For help with the application or to set up a payment plan, contact UPMC's financial specialists at 1-800-371-8359 (option 2).
What insurance does University of Pittsburgh Cancer Institute (UPCI) accept?
The University of Pittsburgh Cancer Institute (UPCI) accepts a variety of insurance plans, including UPMC Health Plan, Aetna, Cigna, United Healthcare, and Highmark. Coverage levels vary by provider, with UPMC Health Plan offering a PPO benefit plan for both in-network and out-of-network services. Additionally, comprehensive student health plans with a modest deductible are available for full-time undergraduate, full-time and part-time graduate students, and pre/post-doctoral fellows & certificate trainees.
What awards or recognition has University of Pittsburgh Cancer Institute (UPCI) received?
The University of Pittsburgh Cancer Institute (UPCI) is renowned for its exceptional clinical and translational research center, specializing in cancer research and experimental therapies. UPMC Hillman Cancer Center, in partnership with UPCI, boasts accreditations from the American College of Radiation Oncology Practice and Quality Oncology Practice Initiative. It is also recognized by the National Cancer Institute as a Comprehensive Cancer Center.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.